The co-founders of Fred Hutch's oncology therapeutics developer include Philip Greenberg who previously helped launch Juno Therapeutics.
Affini-T Therapeutics, a US-based cancer therapy spinout of Fred Hutchinson Cancer Research Center, has closed an oversubscribed $175m round featuring the centre itself and The Parker Institute for Cancer Immunotherapy.
Leaps by Bayer, a subsidiary of pharmaceutical and chemicals group Bayer, and life sciences-focused investment firm Vida Ventures, which co-founded Affini-T, co-led the round, which included Alexandria Venture Investments, a vehicle for life sciences and property investment trust Alexandria Real…
